纳米载体
化学
树枝状大分子
两亲性
合理设计
细胞内
肽
癌症治疗
药品
药物输送
药物发现
联合疗法
癌细胞
生物化学
细胞毒性
对接(动物)
组合化学
生物物理学
纳米医学
毒品携带者
药理学
热休克蛋白
靶向给药
癌症
结构-活动关系
生物信息学
纳米颗粒
抗癌药
癌症治疗
生物活性
作者
Yuanzheng Huang,Chongqin Pan,Baoping Lian,Jiaqian Du,Minxin Cao,Liu Yang,Dan Zhu,Wen Yuan Gao,Lei Wang,Shentong Fang,Xiaoxuan Liu
标识
DOI:10.1021/acs.jmedchem.6c00638
摘要
Conventional single-target drugs frequently suffer from limited efficacy and drug resistance. Here, we report an amphiphilic peptide dendrimer that integrates intrinsic bioactivity and nanocarrier functions, establishing a novel "drug-bioactive carrier" paradigm for multi-target cancer therapy. Using reverse molecular docking and limited proteolysis-mass spectrometry (LiP-MS), heat shock protein 90 (HSP90) was identified as a prominent candidate intracellular target of the dendrimer. Structure-activity relationship studies revealed that amphiphilic balance and dendrimer topology govern self-assembly and HSP90 modulation, with C16-KK2 displaying optimal activity by disrupting HSP90-CDC37 interaction and promoting degradation of oncogenic client proteins. Importantly, C16-KK2 nanoassemblies effectively encapsulate hydrophobic anticancer drugs, enhancing intracellular delivery and yielding synergistic therapeutic effects with rapamycin and sorafenib. In vivo, sorafenib-loaded C16-KK2 nanoparticles exhibited superior tumor accumulation and enhanced antitumor efficacy compared to free drug treatment. This work presents a mechanistically defined and structurally feasible bioactive nanocarrier platform, advancing rational design strategies for multi-target cancer therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI